WO1994000599A3 - Process for detection of neoplastic disease - Google Patents

Process for detection of neoplastic disease Download PDF

Info

Publication number
WO1994000599A3
WO1994000599A3 PCT/US1993/005703 US9305703W WO9400599A3 WO 1994000599 A3 WO1994000599 A3 WO 1994000599A3 US 9305703 W US9305703 W US 9305703W WO 9400599 A3 WO9400599 A3 WO 9400599A3
Authority
WO
WIPO (PCT)
Prior art keywords
detection
neoplastic disease
detect
present
processes
Prior art date
Application number
PCT/US1993/005703
Other languages
French (fr)
Other versions
WO1994000599A2 (en
Inventor
Michael Philip Nova
Ana-Maria Gonzalez
J Andrew Baird
Original Assignee
Whittier Inst Diabetes & Endoc
Prizm Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whittier Inst Diabetes & Endoc, Prizm Pharma Inc filed Critical Whittier Inst Diabetes & Endoc
Priority to DE69304331T priority Critical patent/DE69304331T2/en
Priority to EP93916537A priority patent/EP0646182B1/en
Priority to AU46354/93A priority patent/AU686566B2/en
Publication of WO1994000599A2 publication Critical patent/WO1994000599A2/en
Publication of WO1994000599A3 publication Critical patent/WO1994000599A3/en
Priority to GR960403208T priority patent/GR3021817T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

According to the present invention, processes for detecting the presence of neoplastic disease are provided. The processes involve the detection of a product associated with expression of genes that encode protein receptors for fibroblast growth factor in cells or a product present in a body fluid. Detection can be carried out in a variety of ways, such as by hybridization to detect the presence of mRNA or immunological assays to detect the presence of receptor protein.
PCT/US1993/005703 1992-06-18 1993-06-14 Process for detection of neoplastic disease WO1994000599A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE69304331T DE69304331T2 (en) 1992-06-18 1993-06-14 METHOD FOR DETECTING NEOPLASTIC DISEASES
EP93916537A EP0646182B1 (en) 1992-06-18 1993-06-14 Process for detection of neoplastic disease
AU46354/93A AU686566B2 (en) 1992-06-18 1993-06-14 Process for detection of neoplastic disease
GR960403208T GR3021817T3 (en) 1992-06-18 1996-11-28 Process for detection of neoplastic disease.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90064692A 1992-06-18 1992-06-18
US07/900,646 1992-06-18

Publications (2)

Publication Number Publication Date
WO1994000599A2 WO1994000599A2 (en) 1994-01-06
WO1994000599A3 true WO1994000599A3 (en) 1994-02-17

Family

ID=25412867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005703 WO1994000599A2 (en) 1992-06-18 1993-06-14 Process for detection of neoplastic disease

Country Status (10)

Country Link
US (1) US5670323A (en)
EP (1) EP0646182B1 (en)
AT (1) ATE141958T1 (en)
AU (1) AU686566B2 (en)
CA (1) CA2136439A1 (en)
DE (1) DE69304331T2 (en)
DK (1) DK0646182T3 (en)
ES (1) ES2091018T3 (en)
GR (1) GR3021817T3 (en)
WO (1) WO1994000599A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6446194A (en) * 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
WO1999035159A1 (en) * 1998-01-08 1999-07-15 Brigham & Women's Hospital, Inc. Lymphoma/leukemia oncogene, oncoprotein and methods of use
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
EA201990619A1 (en) 2008-10-10 2019-07-31 Амген Инк. FGF21 MUTANTS AND THEIR APPLICATION
UY32607A (en) 2009-05-05 2010-12-31 Amgen Inc MUTANTS OF FGF21 AND USES OF THE SAME
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
CN116323666A (en) 2020-08-21 2023-06-23 建新公司 FGFR3 antibodies and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341904A2 (en) * 1988-05-09 1989-11-15 Temple University of the Commonwealth System of Higher Education Method for predicting the effectiveness of antineoplastic therapy in individual patients
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
WO1991011459A1 (en) * 1990-01-23 1991-08-08 Farmitalia Carlo Erba S.R.L. Extracellular form of the human fibroblast growth factor receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387777A3 (en) * 1989-03-15 1992-01-02 Takeda Chemical Industries, Ltd. Method for detecting and measuring fgf and for diagnosis of tumor
WO1992004918A1 (en) * 1990-09-19 1992-04-02 The Salk Institute For Biological Studies Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341904A2 (en) * 1988-05-09 1989-11-15 Temple University of the Commonwealth System of Higher Education Method for predicting the effectiveness of antineoplastic therapy in individual patients
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
WO1991011459A1 (en) * 1990-01-23 1991-08-08 Farmitalia Carlo Erba S.R.L. Extracellular form of the human fibroblast growth factor receptor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. ISACCHI ET AL., NUCLEIC ACIDS RESEARCH, vol. 18, no. 7, 1990, ARLINGTON, VIRGINIA US, pages 1906 *
D. BECKER ET AL., ONCOGENE, vol. 7, November 1992 (1992-11-01), pages 2303 - 2313 *
J. PARTANEN ET AL., EMBO JOURNAL, vol. 10, no. 6, 1991, EYNSHAM, OXFORD GB, pages 1347 - 1354 *
M. SENO ET AL.: "Two cDNAs encoding novel human FGF receptor", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1089, 1991, pages 244 - 246 *
NOVA M P ET AL: "THE FIBROBLAST GROWTH FACTOR RECEPTOR AS A DIAGNOSTIC AGENT FOR MALIGNANT MELANOMA.", 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF DERMATOPATHOLOGY, SAN FRANCISCO, CALIFORNIA, USA, DECEMBER 2-4, 1992. J CUTANEOUS PATHOL 19 (6). 1992. 544. CODEN: JCUPBN ISSN: 0303-6987 *
THEILLET C ET AL: "AMPLIFICATION OF FGF -RELATED GENES IN HUMAN TUMORS POSSIBLE INVOLVEMENT OF HST IN BREAST CARCINOMAS.", ONCOGENE 4 (7). 1989. 915-922. CODEN: ONCNES ISSN: 0950-9232 *

Also Published As

Publication number Publication date
CA2136439A1 (en) 1994-01-06
US5670323A (en) 1997-09-23
WO1994000599A2 (en) 1994-01-06
EP0646182B1 (en) 1996-08-28
EP0646182A1 (en) 1995-04-05
ES2091018T3 (en) 1996-10-16
DK0646182T3 (en) 1996-09-16
ATE141958T1 (en) 1996-09-15
DE69304331T2 (en) 1997-01-16
AU686566B2 (en) 1998-02-12
AU4635493A (en) 1994-01-24
DE69304331D1 (en) 1996-10-02
GR3021817T3 (en) 1997-02-28

Similar Documents

Publication Publication Date Title
WO1994000599A3 (en) Process for detection of neoplastic disease
EP1325926A3 (en) Metallocenes
FI891226A (en) RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM.
AU1689297A (en) Chemokine receptors 88-2B(CKR-3) and 88C and their antibodies
CA2079585A1 (en) Ligand for the neu gene product
ES2145015T3 (en) SPECIFIC PROTEASES OF UBIQUITINE.
WO2000050088A3 (en) Biotinylated-chemokine antibody complexes
CA2413156A1 (en) Expression vectors
WO1996009386A3 (en) Allelic variation of the serotonin 5ht2c receptor
Eveleth et al. Internalization and cycling of nerve growth factor in PC12 cells: interconversion of type II (fast) and type I (slow) nerve growth factor receptors
EA200701282A1 (en) PROCESS OF ALKYLATION WITH RECYCLING THE OUTPUT FLOW FROM A TANK FOR DEPRESSION
Tang et al. Retention of a type II surface membrane protein in the endoplasmic reticulum by the Lys-Asp-Glu-Leu sequence.
ATE139260T1 (en) DIAGNOSTIC GENES FOR DETECTING TOXOPLASMOSIS
PL375955A1 (en) Monocyclopentadienyl complexes
Bayer et al. Close similarity among streptavidin-like, biotin-binding proteins from Streptomyces
Gibbons et al. A method for the separation of hybrids of chromatographically identical oligomeric proteins. Use of 3, 4, 5, 6-tetrahydrophthaloyl groups as a reversible" chromatographic handle"
DE3278505D1 (en) Hybridoma antibody which inhibits interleukin-2 activity and its use as a reagent for interleukin-2 detection, the production of said antibody, a process for producing hybrid anti-interleukin-2 antibody producing cells, and such cells
AU4951797A (en) Process for detecting live microbiological contaminants in food product sample
AU6991994A (en) Prostaglandin receptor ep3 and dna encoding it
EP0036336A3 (en) Process for detecting proteins specific to hypertension in mammals
WO1994012669A3 (en) Detection of dna contaminants by pcr
WO2001034808A3 (en) Method of large-scale production and method of testing of the biological activity of a substance from soybean
Haziot et al. Biochemistry of HLA-DRw6: evidence for seven distinct haplotypes.
AU2003258599A8 (en) Monocyclopentadienyl complexes
AU4501893A (en) Flat roof duct

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2136439

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993916537

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 367311

Country of ref document: US

Date of ref document: 19950113

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1993916537

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 1995 477231

Country of ref document: US

Date of ref document: 19950607

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 1993916537

Country of ref document: EP